RESEARCH-USE BIOSIMILAR ANTIBODY
Amubarvimab
Monoclonal antibody · IgG1
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.
TARGETSARS-CoV-2 Spike RBD
YMonoclonal antibody
CATALOGSC-BS-774
CATALOG NUMBERSC-BS-774
MOLECULAR WEIGHTApprox. 143.84 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.
Amubarvimab is a recombinant research-use antibody directed against SARS-CoV-2 Spike RBD.